Commercial Offices to Support local Cell and Gene Therapy Sector

Growth in demand across the Chinese cell and gene therapy (C>) sector has seen Strasbourg-based Polyplus moving into premium office space in Shanghai’s Changning District increasing its footprint and service offering in China. “Our Shanghai team offers advanced scientific support and supply solutions for upstream processing technologies of pre-clinical, clinical and commercial cell and gene therapies manufacturing,” said Dr Jacob Qin, China Business Director at Polyplus.

Founded in 2001, Polyplus was established to provide research support tailored to meet scientific and regulatory standards of clinical development phases supplying a growing range of transfection reagents worldwide. Its growth in the Asia-Pacific region began with the acquisition of Biowire, a Hong Kong based company supporting commercial development of life sciences tool and reagent companies in Asia.

“Innovation in gene replacement therapy using Adeno Associated Virus (AAV) and gene modified cell therapies using lentiviral vectors (LV) is advancing rapidly across the globe. China has been a frontrunner in this race to new therapeutic modalities progress,” said Mario Philips, CEO of Polyplus. “This growth has created tremendous demand for high performance, high quality transfection reagents, particularly for AAV gene therapy and CAR-T cell therapy treatments, in the region. We believe it is critical to invest in a physical presence in this market as we work to strategically expand our portfolio of products and services globally.”

The company continues to invest in other global regions, including construction of a 4000 m2 global headquarters at the Vectura facility in France (International Labmate, April 2021), due to complete in Q3 this year.

More information online